公开(公告)号：US12193998B2

公开(公告)日：2025-01-14

申请号：US17738418

申请日：2022-05-06

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Colette Song ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC: A61K39/00 ,  A61K35/17 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/705 ,  C07K14/71 ,  C07K14/72 ,  C07K14/725 ,  C07K14/81 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C07K16/38 ,  C07K16/40 ,  C12N5/0783 ,  C12N9/02 ,  C12N9/12 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/574 ,  G16B25/00 ,  G16B25/10 ,  A61K38/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US12193997B2

公开(公告)日：2025-01-14

申请号：US17735000

申请日：2022-05-02

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Colette Song ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC: A61K39/00 ,  A61K35/17 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47 ,  C07K14/705 ,  C07K14/71 ,  C07K14/72 ,  C07K14/725 ,  C07K14/81 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C07K16/38 ,  C07K16/40 ,  C12N5/0783 ,  C12N9/02 ,  C12N9/12 ,  C12N15/115 ,  C12Q1/6886 ,  G01N33/574 ,  G16B25/00 ,  G16B25/10 ,  A61K38/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US12070541B2

公开(公告)日：2024-08-27

申请号：US18323077

申请日：2023-05-24

Applicant: Orth Consulting, LLC

Inventor： Donald S. Orth ,  Roger W. Orth

IPC: A61M1/34 ,  A61F2/01 ,  A61F2/95 ,  A61K8/66 ,  A61M1/14 ,  A61M1/16 ,  A61M1/26 ,  A61M1/36 ,  B01D63/02 ,  B01D63/06 ,  B01D69/04 ,  B01D69/08 ,  B01J31/00 ,  C07K16/00 ,  C07K16/38 ,  C07K16/40 ,  C12N9/22 ,  C12N11/00 ,  C12N11/04 ,  C12N11/06 ,  C12N11/14 ,  C12N11/16

CPC classification number: A61M1/3489 ,  A61F2/01 ,  A61F2/95 ,  A61K8/66 ,  A61M1/15632 ,  A61M1/1621 ,  A61M1/1678 ,  A61M1/267 ,  A61M1/36 ,  A61M1/3601 ,  A61M1/3618 ,  A61M1/3621 ,  A61M1/3679 ,  A61M1/3687 ,  A61M1/3689 ,  B01D63/02 ,  B01D63/06 ,  B01D69/04 ,  B01D69/043 ,  B01D69/08 ,  B01J31/00 ,  B01J31/003 ,  C07K16/00 ,  C07K16/38 ,  C07K16/40 ,  C12N9/22 ,  C12N11/00 ,  C12N11/04 ,  C12N11/06 ,  C12N11/14 ,  C12N11/16 ,  A61M2202/0445 ,  A61M2205/3303 ,  A61M2205/3368

Abstract: A blood treatment method includes the steps of inducing flow of a patient's blood through a blood treatment device inlet and outlet in fluid connection to the circulatory system of the patient. Metastatic deoxyribonucleic acid (DNA) contained within patient blood is destroyed by passing a patient's blood over a bioreactor surface having attached or immobilized deoxyribonuclease 1 (DNase 1) enzyme. The blood treatment device which consists of a bioreactor containing immobilized DNase 1, enables continuous treatment of a patient's blood and increases the effective concentration of DNase 1 in a patient's bloodstream to convert metastasizing cancer DNA in blood into non-oncogenic nucleotide fragments in vivo without adding any chemicals to the blood of the patient.

公开(公告)号：US11774447B2

公开(公告)日：2023-10-03

申请号：US16625972

申请日：2018-07-02

Applicant: University of Tsukuba

Inventor： Isao Matsumoto ,  Takayuki Sumida ,  Hoshimi Kawaguchi

IPC: G01N33/564 ,  C07K16/38

CPC classification number: G01N33/564 ,  C07K16/38 ,  G01N2333/811 ,  G01N2440/18

Abstract: This invention provides a method for diagnosis of rheumatoid arthritis of a subject, a method for assisting diagnosis of rheumatoid arthritis, and a method for monitoring disease activity of rheumatoid arthritis and/or therapeutic effects of an agent for rheumatoid arthritis, comprising detecting citrullination of an arginine residue of the inter-α-trypsin inhibitor heavy chain (ITIH) 4 in a biological sample obtained from the subject. This invention also provides a citrullinated protein derived from the protein having the amino acid sequence as shown in SEQ ID NO: 1 or 5 by modification of arginine 438 into citrulline or a fragment thereof, an antibody binding to such citrullinated protein, and an agent for diagnosis of rheumatoid arthritis comprising such antibody.

公开(公告)号：US20220354936A1

公开(公告)日：2022-11-10

申请号：US17345517

申请日：2021-06-11

Applicant: Immatics Bioechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Herpreet SINGH

IPC: A61K39/00 ,  C07K7/08 ,  C12N15/115 ,  C12N5/0783 ,  C07K14/71 ,  C07K14/725 ,  C07K16/28 ,  C12Q1/6886 ,  C07K16/18 ,  G01N33/574 ,  C07K14/47 ,  C07K16/30 ,  C07K7/06 ,  C07K14/72 ,  C12N9/12 ,  C07K16/38 ,  C07K14/81 ,  C07K16/40 ,  C12N9/02 ,  C07K14/705 ,  G16B25/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20220325000A1

公开(公告)日：2022-10-13

申请号：US17639139

申请日：2020-08-28

Applicant: Suzhou Alphamab Co., Ltd.

Inventor： Ting Xu ,  Xiaoxiao Wang ,  Ying Fan ,  Yanrong Dong ,  Liping Chen ,  Jianyun Ji

IPC: C07K16/38 ,  A61P7/04

Abstract: Disclosed is a monoclonal antibody or an antigen binding fragment thereof which targets tissue factor pathway inhibitor (TFPI), and a medical use thereof.

公开(公告)号：US20220280623A1

公开(公告)日：2022-09-08

申请号：US17743778

申请日：2022-05-13

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00 ,  C07K16/28 ,  C07K14/705 ,  C07K7/08 ,  G16B25/10 ,  C12N9/12 ,  C07K7/06 ,  C07K16/40 ,  C07K14/71 ,  C07K14/47 ,  C12N15/115 ,  C12N9/02 ,  C12N5/0783 ,  C12Q1/6886 ,  C07K16/30 ,  G16B25/00 ,  C07K14/72 ,  C07K16/18 ,  C07K16/38 ,  G01N33/574 ,  C07K14/725 ,  C07K14/81

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US20220265794A1

公开(公告)日：2022-08-25

申请号：US17738418

申请日：2022-05-06

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea MAHR ,  Toni WEINSCHENK ,  Colette SONG ,  Oliver SCHOOR ,  Jens FRITSCHE ,  Harpreet SINGH

IPC: A61K39/00 ,  C07K16/28 ,  C07K14/705 ,  C07K7/08 ,  G16B25/10 ,  C12N9/12 ,  C07K7/06 ,  C07K16/40 ,  C07K14/71 ,  C07K14/47 ,  C12N15/115 ,  C12N9/02 ,  C12N5/0783 ,  C12Q1/6886 ,  C07K16/30 ,  G16B25/00 ,  C07K14/72 ,  C07K16/18 ,  C07K16/38 ,  G01N33/574 ,  C07K14/725 ,  C07K14/81

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.

公开(公告)号：US11320436B2

公开(公告)日：2022-05-03

申请号：US17377473

申请日：2021-07-16

Applicant: IMMUNOVIA AB

Inventor： Payam Delfani ,  Linda Dexlin Mellby ,  Anders Carlsson ,  Björn Elleby

IPC: G01N33/543 ,  G01N33/574 ,  C07K16/18 ,  C07K16/28 ,  C07K16/30 ,  C07K16/38 ,  C07K16/40

Abstract: The present invention provides a method for diagnosing or determining a pancreatic cancer-associated disease state comprising or consisting of the steps of: (a) providing a sample from an individual to be tested; and (b) determining a biomarker signature of the test sample by measuring the presence and/or amount in the test sample of two or more biomarkers selected from the group defined in Table A; wherein the presence and/or amount in the test sample of two or more biomarkers selected from the group defined in Table A is indicative of the pancreatic cancer-associated disease state in the individual; uses and methods of determining a pancreatic cancer-associated disease state, and methods of treating pancreatic cancer, together with arrays and kits for use in the same.

公开(公告)号：US11235042B2

公开(公告)日：2022-02-01

申请号：US17339303

申请日：2021-06-04

Applicant: Immatics Biotechnologies GmbH

Inventor： Andrea Mahr ,  Toni Weinschenk ,  Colette Song ,  Oliver Schoor ,  Jens Fritsche ,  Harpreet Singh

IPC: A61K39/00 ,  C07K7/08 ,  C12N15/115 ,  C12N5/0783 ,  C07K14/71 ,  C07K14/725 ,  C07K16/28 ,  C12Q1/6886 ,  C07K16/18 ,  G01N33/574 ,  C07K14/47 ,  C07K16/30 ,  C07K7/06 ,  C07K14/72 ,  C12N9/12 ,  C07K16/38 ,  C07K14/81 ,  C07K16/40 ,  C12N9/02 ,  C07K14/705 ,  G16B25/00 ,  A61K35/17 ,  A61K38/00

Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.